Drug
Setmelanotide clinical trials
Also written RM-493 and Imcivree.
- studies test it
- 25
- open now
- 3
- in phase 3
- 10
- first study started
- 2012
Keep track of what changes. Save the setmelanotide studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
25 studies that test it; most in 2021 (5)
| Year | Studies |
|---|---|
| 2012 | 1 |
| 2013 | 2 |
| 2014 | 1 |
| 2015 | 2 |
| 2017 | 3 |
| 2018 | 3 |
| 2020 | 1 |
| 2021 | 5 |
| 2022 | 1 |
| 2023 | 2 |
| 2024 | 1 |
| 2025 | 2 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 4
- Phase 2
- 11
- Phase 3
- 10
- Phase 4
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 22 · Other 3
Rhythm Pharmaceuticals, Inc. (22) · Massachusetts General Hospital (1) · Tom Hühne (1) · Charite University, Berlin, Germany (1)
Studies
Open first, then newest update. How each study uses setmelanotide is read from its arms, and is right about nine times in ten.
Testing it · 25
- Setmelanotide to Treat Obesity in a Patient With Pseudohypoparathyroidism Type 1a (PHP1a)Enrolling by invitationPhase 2Massachusetts General HospitalNCT07496463Written as Setmelanotide
- Real-World Effects of MC4R Agonist Therapy in BBS and Severe Genetic ObesityRecruitingPhase 4Tom HühneNCT07674290Written as Setmelanotide
- A Trial of Setmelanotide in Patients With Congenital Hypothalamic Obesity (Sub-study of NCT05774756)RecruitingPhase 3Rhythm Pharmaceuticals, Inc.NCT06760546Written as Setmelanotide
- A Trial of Setmelanotide in Acquired Hypothalamic ObesityActive, not recruitingPhase 3Rhythm Pharmaceuticals, Inc.NCT05774756Written as Setmelanotide
- EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R PathwayCompletedPhase 3Rhythm Pharmaceuticals, Inc.NCT05093634Written as Setmelanotide
- Open-Label Extension Study of SetmelanotideCompletedPhase 3Rhythm Pharmaceuticals, Inc.NCT06596135Written as Setmelanotide
- A Study of Setmelanotide in Patients With Prader-Willi SyndromeActive, not recruitingPhase 2Rhythm Pharmaceuticals, Inc.NCT06772597Written as Setmelanotide
- DAYBREAK: A Study of Setmelanotide in Participants With Specific Gene Variants in the Melanocortin-4 Receptor (MC4R) PathwayCompletedPhase 2Rhythm Pharmaceuticals, Inc.NCT04963231Written as Setmelanotide
- Long Term Extension Trial of SetmelanotideCompletedPhase 2/3Rhythm Pharmaceuticals, Inc.NCT03651765Written as Setmelanotide
- Open-Label Study of Setmelanotide in Hypothalamic ObesityCompletedPhase 2Rhythm Pharmaceuticals, Inc.NCT04725240Written as Setmelanotide
- Setmelanotide in Pediatric Participants With Rare Genetic Diseases of ObesityCompletedPhase 3Rhythm Pharmaceuticals, Inc.NCT04966741Written as Setmelanotide
- Phase 3 Crossover Trial of Two Formulations of Setmelanotide in Participants With Specific Gene Defects in the MC4R PathwayCompletedPhase 3Rhythm Pharmaceuticals, Inc.NCT05194124Written as Setmelanotide 2 mg
- Study of Setmelanotide Effects on QTc (Corrected QT) Interval in Healthy ParticipantsCompletedPhase 4Rhythm Pharmaceuticals, Inc.NCT05046132Written as Setmelanotide
- Setmelanotide (RM-493), Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Participants With Moderate to Severe ObesityCompletedPhase 3Rhythm Pharmaceuticals, Inc.NCT03746522Written as Setmelanotide
- Setmelanotide for the Treatment of Early-Onset Pro-Opiomelanocortin (POMC) Deficiency ObesityCompletedPhase 3Rhythm Pharmaceuticals, Inc.NCT02896192Written as Setmelanotide
- Setmelanotide Phase 2 Treatment Trial in Participants With Rare Genetic Disorders of ObesityCompletedPhase 2Rhythm Pharmaceuticals, Inc.NCT03013543Written as Setmelanotide
- Phase 2 Study to Evaluate Safety and Efficacy of RM-493 in Obese ParticipantsCompletedPhase 2Rhythm Pharmaceuticals, Inc.NCT01749137Written as Setmelanotide
- Phase 1b/2a Study to Evaluate Safety and Efficacy of Setmelanotide in Obese PatientsCompletedPhase 1/2Rhythm Pharmaceuticals, Inc.NCT02041195Written as Setmelanotide
- Phase 2 Trial to Evaluate Safety and Efficacy of Setmelanotide (RM-493) in Obese Participants With Prader-Willi SyndromeCompletedPhase 2Rhythm Pharmaceuticals, Inc.NCT02311673Written as Setmelanotide
- Setmelanotide for the Treatment of Leptin Receptor (LEPR) Deficiency ObesityCompletedPhase 3Rhythm Pharmaceuticals, Inc.NCT03287960Written as Setmelanotide
Codes
What other systems call setmelanotide · ClinicalTrials.gg INT006260
- MeSH (NLM) C579663setmelanotideOne source ClinicalTrials.gov
- UNII (FDA) N7T15V1FUYSETMELANOTIDEConfirmed FDA, Wikidata
- RxNorm 2469247One source FDA
- Wikidata Q21098917setmelanotideConfirmed FDA, Wikidata
- NCI Thesaurus C152349SetmelanotideOne source FDA
- DrugBank DB11700One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C579663 | setmelanotide | One source ClinicalTrials.gov |
| UNII (FDA) | N7T15V1FUY | SETMELANOTIDE | Confirmed FDA, Wikidata |
| RxNorm | 2469247 | — | One source FDA |
| Wikidata | Q21098917 | setmelanotide | Confirmed FDA, Wikidata |
| NCI Thesaurus | C152349 | Setmelanotide | One source FDA |
| DrugBank | DB11700 | — | One source Wikidata |
Also registered as setmelanotide acetate (UNII 224I1W20I7 · RxNorm 2469248).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.